FDA Clears Prelude’s Experimental Cancer Drug, Opening New Path for Blood Disorders
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) said the U.S. Food and Drug Administration has cleared its investigational new drug application for PRT12396, allowing the company to begin a …
FDA Clears Prelude’s Experimental Cancer Drug, Opening New Path for Blood Disorders Read More